120 related articles for article (PubMed ID: 2149510)
1. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.
Nicholson RI; Walker KJ; McClelland RA; Dixon A; Robertson JF; Blamey RW
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):989-95. PubMed ID: 2149510
[TBL] [Abstract][Full Text] [Related]
2. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
[TBL] [Abstract][Full Text] [Related]
3. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
[TBL] [Abstract][Full Text] [Related]
4. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
Robertson JF; Walker KJ; Nicholson RI; Blamey RW
Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
[TBL] [Abstract][Full Text] [Related]
5. Zoladex in advanced breast cancer.
Robertson JF; Nicholson RI; Walker KJ; Blamey RW
Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
[TBL] [Abstract][Full Text] [Related]
6. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
7. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex.
Robert NJ; Dalton WS; Osborne CK; Abeloff M
Horm Res; 1989; 32 Suppl 1():221-2. PubMed ID: 2533155
[TBL] [Abstract][Full Text] [Related]
8. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
Williams MR; Walker KJ; Turkes A; Blamey RW; Nicholson RI
Br J Cancer; 1986 May; 53(5):629-36. PubMed ID: 2941044
[TBL] [Abstract][Full Text] [Related]
9. Zoladex: therapeutic effects in postmenopausal breast cancer.
Harris AL; Carmichael J; Cantwell BM; Dowsett M
Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
[TBL] [Abstract][Full Text] [Related]
10. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
11. Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects.
Nicholson RI; Walker KJ; Bouzubar N; Wills RJ; Gee JM; Rushmere NK; Davies P
Ann N Y Acad Sci; 1990; 595():316-27. PubMed ID: 2142873
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
Kim JY; Im SA; Jung KH; Ro J; Sohn J; Kim JH; Park YH; Kim TY; Kim SB; Lee KS; Kim GM; Kim SH; Kim S; Ahn JS; Lee KH; Ahn JH; Park IH; Im YH;
Eur J Cancer; 2018 Nov; 103():127-136. PubMed ID: 30223226
[TBL] [Abstract][Full Text] [Related]
13. LHRH analogues in early breast cancer.
Jonat W
Horm Res; 1989; 32 Suppl 1():223-5. PubMed ID: 2533156
[TBL] [Abstract][Full Text] [Related]
14. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
Robertson JF; Bates K; Pearson D; Blamey RW; Nicholson RI
Br J Cancer; 1992 May; 65(5):727-30. PubMed ID: 1534019
[TBL] [Abstract][Full Text] [Related]
16. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study.
Berglund G; Nystedt M; Bolund C; Sjödén PO; Rutquist LE
J Clin Oncol; 2001 Jun; 19(11):2788-96. PubMed ID: 11387349
[TBL] [Abstract][Full Text] [Related]
17. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study.
Baum M; Hackshaw A; Houghton J; Rutqvist ; Fornander T; Nordenskjold B; Nicolucci A; Sainsbury R;
Eur J Cancer; 2006 May; 42(7):895-904. PubMed ID: 16545560
[TBL] [Abstract][Full Text] [Related]
19. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
Robertson JF; Blamey RW
Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
[TBL] [Abstract][Full Text] [Related]
20. Zoladex in the treatment of premenopausal metastatic breast cancer patients.
Kaufmann M
Horm Res; 1989; 32 Suppl 1():202-5. PubMed ID: 2533150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
